ESO-51

Cat.No.: CSC-C0675

Species: Homo sapiens (Human)

Source: Esophagus

Morphology: polymorphic cells growing in clusters in suspension

Culture Properties: suspension

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C0675

Description

Established from the primary tumor of a 74-year-old white man with esophageal adenocarcinoma in 2000

Species

Homo sapiens (Human)

Source

Esophagus

Recommended Medium

80-90% RPMI-1640 + 10-20% h.i. FBS

Culture Properties

suspension

Morphology

polymorphic cells growing in clusters in suspension

Karyotype

Human flat bimodal hyperdiploid/hypertetraploid karyotype; 51-63/90-121<4n>XXXX, -Y, -Y, -Y, -Y, + 5-12mar; add(X)(p11)x2, del(2)(q21)x2, dup(2)(q11q24)i(2)(q10), dup(3)(q24q29), i(3)(p10), add(3)(p25), add(7)(q21)(hsr)x2, del(13)(q11q13), add(17)(q 25),

Disease

Esophageal Adenocarcinoma

Quality Control

Mycoplasma: negative in microbiological culture, PCR assays
Immunology: cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin +
Viruses: PCR:

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO; ship in dry ice; store in liquid nitrogen

Synonyms

ESO51

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

ESO-51 is a well-characterized human cell line derived from a primary adenocarcinoma of the distal esophagus. It was established in 2000 from a 74-year-old Caucasian male, with the presence of Barrett's transformed mucosa, reflecting the metaplasia-dysplasia-adenocarcinoma sequence central to esophageal adenocarcinoma (EAC) pathogenesis. The line exhibits a polymorphic morphology, growing in large spherical clusters in suspension, and is tumorigenic in immunocompromised mice, confirming its malignant phenotype.

ESO-51 is a highly valuable model for mechanistic studies of Barrett's-associated carcinogenesis, drug sensitivity assays, and comparative genomic analyses of EAC. Its suspension growth in RPMI-1640 medium offers practical handling advantages, enabling large-scale expansion for high-throughput screening. Given the limited availability of authentic EAC models, ESO-51 serves as a crucial tool for unraveling the molecular drivers of this aggressive malignancy and for preclinical therapeutic evaluation.

Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma

Oesophageal adenocarcinoma is a rapidly increasing problem in which treatment options are limited. Previous studies have shown that oesophageal adenocarcinoma cells and tissues express oestrogen receptors (ERs) and show growth suppression and apoptosis in response to ER modulator agents such as tamoxifen. ERs are known to be expressed in a number of isoforms that act together to regulate cell growth and cell death.

In this study, Due, Steven L., et al. used western blotting to profile the expression of ERα and ERβ isoforms, and expression of the oncologically related molecules p53, HER2, and EGFR, in a panel of oesophageal adenocarcinoma cell lines. The cytotoxicity of tamoxifen in the cell lines was determined with Annexin V-FITC flow cytometry, and correlations between cytotoxicity and receptor expression were assessed using Spearman's rank-order correlation. Oesophageal adenocarcinoma cell lines showed varying cytotoxicity in response to tamoxifen. The ER species ERα90, ERα50, and ERα46, as well as p53, were positively associated with a cytotoxic response. Conversely, ERα74, ERα70, and ERβ54 were associated with a lack of cytotoxic response. The ER species detected in oesophageal adenocarcinoma cells may work together to confer sensitivity to ER modulators in this disease, which could open up a new avenue for therapy in selected patients.